Category: Politics

Heavy and consistent alcohol consumption significantly increases the risk of colorectal cancer, according to a new study involving over 88,000 U.S. adults.

Heavy drinking over a lifetime is linked to an elevated risk of colorectal cancer, according to a study published in the journal *Cancer* by the American Cancer Society (ACS). The research analyzed two decades of data from more than 88,000 U.S. adults to assess how long-term alcohol consumption affects the likelihood of developing colorectal cancer (CRC) or precancerous colorectal adenomas, commonly known as polyps.

Participants in the study reported their average weekly intake of beer, wine, and liquor during four distinct age periods: 18 to 24, 25 to 39, 40 to 54, and 55 and older. The study categorized “heavy drinkers” as those consuming more than 14 drinks per week, while “moderate drinkers” were defined as those having between seven and 14 drinks weekly.

The observational research found a strong correlation between consistent heavy drinking throughout adulthood and an increased risk of colorectal cancer, particularly rectal cancer. Specifically, heavy lifetime drinking was associated with a 25% higher overall risk of CRC and nearly double the risk of rectal cancer. In contrast, moderate drinking was linked to a lower overall CRC risk. When compared to light drinkers, those who consistently engaged in heavy drinking had an approximately 91% higher risk of developing CRC.

Regarding colorectal adenomas, the study did not find a significant pattern linking higher current lifetime drinking to these precancerous polyps. However, former drinkers exhibited a notably lower risk of non-advanced adenomas compared to current light drinkers.

Out of the 88,092 participants, 1,679 were diagnosed with colorectal cancer during the study period. The authors acknowledged limitations in their research, noting that it was observational rather than based on a clinical trial, and relied on self-reported alcohol consumption.

The findings suggest that consistently heavy alcohol intake and higher average lifetime consumption may elevate CRC risk, while cessation of drinking could reduce the risk of adenomas. The researchers also indicated that the associations might vary depending on the tumor site.

The connection between alcohol consumption and cancer is not a new revelation. In a recent episode of *The Dr. Mark Hyman Show*, Dr. Mark Hyman, chief medical officer of Function Health in California, discussed how even moderate drinking can adversely affect nearly every organ system in the body. He attributed this to metabolic stress, inflammation, impaired detoxification, and hormonal disruptions caused by alcohol.

Dr. Hyman emphasized that drinking increases the risk of various cancers, metabolic dysfunction, disturbances in the gut microbiome, and mitochondrial toxins. He stated, “Bottom line, alcohol taxes every major system in your body, especially your liver, your brain, your gut, and your hormones.”

In a previous interview with Fox News Digital, Dr. Pinchieh Chiang, a clinician at Circle Medical in San Francisco, noted that taking extended breaks from alcohol can lead to profound health improvements. “Over months to a year, we see sustained improvements in blood pressure, liver function, and inflammation,” she said. “Those changes directly affect long-term heart disease and stroke risk.” Dr. Chiang added that reducing or eliminating alcohol consumption over time lowers the risk of several cancers, including breast and colorectal cancer.

As the research continues to unfold, it is clear that the implications of alcohol consumption on health, particularly regarding cancer risk, warrant further attention and consideration.

These findings underscore the importance of understanding the long-term effects of alcohol consumption on health and the potential benefits of moderation or abstinence. For those concerned about their drinking habits, consulting healthcare professionals can provide valuable insights and guidance.

For more information on this study and its implications, please refer to the original research published in *Cancer*.

According to Fox News Digital, the study highlights the critical need for awareness regarding alcohol consumption and its potential health risks.

Revati Shreeniwas has been appointed Chief Medical Officer of Aspen Neuroscience to advance the company’s cell therapy for Parkinson’s disease, enhancing its commercial readiness.

Aspen Neuroscience, a clinical-stage biotechnology company, has announced the appointment of Revati Shreeniwas as Chief Medical Officer (CMO). Her role will focus on accelerating the late-stage development and commercial readiness of the company’s innovative cell therapy for Parkinson’s disease.

This leadership change is part of Aspen’s strategy to transition its programs from clinical trials to market with integrity and purpose. The San Diego-based company is pioneering autologous regenerative therapies aimed at addressing neurodegenerative diseases.

Dr. Shreeniwas brings a wealth of experience to her new position, having received her medical education from Armed Forces Medical College in Pune, India. She possesses extensive expertise in neuromuscular and central nervous system (CNS) diseases, orphan indications, cardiovascular and respiratory diseases, as well as gene therapy.

With over 20 years of experience in the biopharma industry, Dr. Shreeniwas is a board-certified physician executive who has held multiple roles as CMO. She has a proven track record of advancing clinical programs from pre-Investigational New Drug (IND) applications through to registration, successfully navigating global regulatory pathways, and shaping clinical and medical strategies for venture-backed companies.

Throughout her career, she has designed and led more than 40 global clinical trials, including registrational studies. Her contributions have been pivotal in the approval and commercialization of several notable therapies, including Rytary for Parkinson’s disease, Sunosi for sleep disorders, Esbriet for idiopathic pulmonary fibrosis (IPF), and Tracleer for pulmonary hypertension.

Expressing her enthusiasm for her new role, Dr. Shreeniwas stated, “Aspen’s autologous iPSC-derived approach is redefining what’s possible in neurodegenerative disease. I’m excited to help deliver a rigorous registrational program for Parkinson’s patients, partnering across clinical, regulatory, technical operations, and medical affairs.”

Before joining Aspen, Dr. Shreeniwas held senior clinical positions at several biopharmaceutical companies, including Cystetic Medicines, Excision BioTherapeutics, Bright Minds Biosciences, and Soleno Therapeutics. She has also held faculty appointments at prestigious institutions such as Columbia University and Stanford University.

Aspen’s investigational therapy, ANPD001, is recognized as the most advanced autologous cell therapy in the United States for the treatment of Parkinson’s disease. The company’s personalized approach eliminates the need for immunosuppressive (IS) drugs, which are typically required to mitigate the body’s immune response against foreign cells. This innovative strategy aims to reduce IS-associated adverse events, eliminate IS drug-monitoring requirements, and facilitate dosing for patients who have contraindications to IS therapies.

ANPD001 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), highlighting its potential significance in treating Parkinson’s disease. The ASPIRO trial, which is the first multi-patient, multi-center clinical trial of an autologous cell therapy for this condition, is currently underway. It is evaluating the safety, tolerability, and preliminary efficacy of ANPD001 in levodopa-responsive patients aged 50 to 70. Primary endpoints are expected to be reported at 12 months, with long-term follow-up extending up to 15 years.

This strategic appointment of Dr. Shreeniwas is expected to significantly enhance Aspen Neuroscience’s efforts in bringing innovative solutions to patients suffering from Parkinson’s disease, according to The American Bazaar.

A new review highlights the growing threat of the drug-resistant fungus Candida auris in U.S. hospitals, while researchers identify potential weaknesses that could lead to new treatments.

Researchers have uncovered a possible vulnerability in the deadly hospital superbug Candida auris (C. auris), which could pave the way for new treatments for this drug-resistant fungal infection. The findings come as the fungus continues to spread rapidly through U.S. hospitals and poses an increasing threat globally.

Described as a “superbug fungus,” C. auris has garnered attention from health officials due to its ability to resist human immune systems. A recent scientific review published by researchers from the Hackensack Meridian Center for Discovery and Innovation (CDI) emphasizes the urgent need for new strategies to combat this pathogen. The review was published in early December and reinforces previous warnings from the Centers for Disease Control and Prevention (CDC), which has labeled C. auris an “urgent antimicrobial threat.” This designation marks the first time a fungal pathogen has received such a classification.

According to the CDC, approximately 7,000 cases of C. auris were reported across dozens of U.S. states in 2025, with the fungus identified in at least 60 countries worldwide. The review, conducted by Dr. Neeraj Chauhan of the Hackensack Meridian CDI, Dr. Anuradha Chowdhary from the University of Delhi’s Medical Mycology Unit, and Dr. Michail Lionakis, chief of the clinical mycology program at the National Institutes of Health, highlights the challenges in containing the pathogen. The researchers point out that outdated diagnostic methods and limited treatment options hinder effective responses to C. auris outbreaks.

The researchers stress the importance of developing “novel antifungal agents with broad-spectrum activity against human fungal pathogens,” as well as improving diagnostic tests and creating immune- and vaccine-based adjunct modalities for treating high-risk patients. They also advocate for increased awareness of fungal diseases and the establishment of better surveillance mechanisms, particularly in resource-limited countries. These advancements are crucial for improving outcomes for patients affected by opportunistic fungal infections.

C. auris was first identified in 2009 from a patient’s ear sample in Japan and has since spread to numerous countries, including the United States. Outbreaks of the fungus have led to the shutdown of some hospital intensive care units, underscoring its potential severity. The greatest risk from C. auris is posed to individuals who are critically ill, particularly those on ventilators or with compromised immune systems. Estimates suggest that about half of infected patients may die from the infection.

Unlike many other fungi, C. auris can survive on human skin and adhere to hospital surfaces and medical equipment, facilitating its spread in healthcare environments. Dr. Marc Siegel, a senior medical analyst at Fox News and clinical professor of medicine at NYU Langone, noted that the fungus is resistant to multiple antifungal drugs and often spreads through equipment used on immunocompromised patients, such as ventilators and catheters. Moreover, C. auris is frequently misdiagnosed, which can delay necessary treatment and infection control measures.

Dr. Siegel has previously highlighted the challenges posed by the symptoms of C. auris, which can include fever, chills, and body aches—symptoms that are common to many infections, leading to potential misdiagnoses. He indicated that research is ongoing to develop new treatments, as only four major classes of antifungal drugs are currently available, with C. auris demonstrating resistance to many of them. Although three new antifungal drugs have been approved or are in late-stage trials, researchers caution that drug development has struggled to keep pace with the fungus’s rapid evolution.

Despite these alarming findings, there is a glimmer of hope. In separate research published in December, scientists at the University of Exeter in England discovered a potential weakness in C. auris while studying the fungus in a living-host model. The research team found that during infection, the fungus activates specific genes to scavenge iron, a crucial nutrient for its survival. They believe that drugs targeting this process could halt infections or even allow for the repurposing of existing medications.

“We think our research may have revealed an Achilles’ heel in this lethal pathogen during active infection,” said Dr. Hugh Gifford, a clinical lecturer at the University of Exeter and co-author of the study. As researchers continue to explore the complexities of C. auris, health officials emphasize the importance of strict infection control measures, rapid detection, and sustained investment in new treatments.

Health experts want to reassure the public that C. auris primarily poses a threat to individuals with weakened immune systems and is not a danger to healthy individuals. As the situation evolves, ongoing research and vigilance will be essential in combating this formidable pathogen.

Fox News Digital has reached out to the CDI researchers and additional experts for further commentary on this pressing health issue. According to Fox News Digital, the fight against C. auris continues as researchers strive to develop effective treatments and preventive measures.

A new drug combination shows promise for treating acute myeloid leukemia (AML) patients resistant to standard therapies, offering hope for improved outcomes in this aggressive cancer.

Researchers at Oregon Health and Science University (OHSU) have made a significant breakthrough in the treatment of acute myeloid leukemia (AML), a particularly aggressive form of leukemia that affects over 20,000 Americans each year. Their findings suggest that a novel drug combination could help patients who do not respond to traditional therapies.

The study involved analyzing samples from more than 300 AML patients, revealing that pairing venetoclax—a drug commonly used to treat leukemia—with palbociclib, which is typically used for breast cancer, produced stronger and more durable leukemia-fighting effects than venetoclax alone.

Jeffrey Tyner, a professor of cell, developmental, and cancer biology at OHSU’s School of Medicine and the Knight Cancer Institute, emphasized the significance of the findings. “The data show that this drug regimen may be especially effective in patients whose tumors exhibit features that cause resistance to the current standard of care, frontline therapies,” he stated.

The research team initially explored a wide range of drug combinations without any predetermined favorites. Among all the pairings tested, including existing standard-of-care regimens, the combination of venetoclax and palbociclib emerged as the most promising.

Melissa Stewart, a research assistant professor at OHSU and the lead author of the study, noted, “That really motivated us to dig deeper into why it works so well—and why it appears to overcome resistance seen with current therapy.” The study revealed that AML cells exposed solely to venetoclax could adapt by increasing protein production, allowing them to survive. However, the addition of palbociclib blocked this adaptation, significantly impeding the cancer cells’ ability to thrive.

In preclinical models, the results were striking. While venetoclax alone did not extend survival, the combination treatment resulted in the majority of mice living for 11 to 12 months, with one mouse still alive at the conclusion of the study.

Tyner explained that the study sheds light on the biological mechanisms behind the improved outcomes associated with this new drug combination, paving the way for future clinical trials involving real patients. “Unfortunately, almost everyone will eventually have drug resistance,” he remarked, highlighting the ongoing challenges in treating AML.

Despite the promising initial response rates and improved quality of life reported with the current drug regimen, the five-year survival rate for AML remains low, estimated at only 25% to 40%. “We have a lot of work to do,” Tyner added.

While the data strongly suggest that this new drug combination should be tested in clinical trials, the research team acknowledges that they currently lack data on its clinical activity in AML patients, aside from some anecdotal reports. “So, the biggest limitation is also our desired next step—of testing this new drug combination in clinical trials,” Tyner concluded.

As the medical community continues to seek innovative solutions for AML, this research offers a glimmer of hope for patients facing treatment-resistant forms of the disease.

For further details, refer to the original report from Fox News Digital.

Global omega-3 deficiency affects 76% of people worldwide, significantly increasing risks for heart disease, cognitive decline, and chronic inflammation, according to a new study.

A recent analysis has revealed that more than three-quarters of the global population is not meeting the recommended intake levels of omega-3 fatty acids, a nutrient gap that could lead to increased risks of heart disease, cognitive decline, chronic inflammation, and vision problems. This finding comes from a study published in *Nutrition Research Reviews*, conducted by researchers from the University of East Anglia, the University of Southampton, and Holland & Barrett.

The review indicates that 76% of individuals worldwide are falling short of the recommended daily intake of two essential omega-3 fats: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Global health authorities recommend that most adults aim for at least 250 milligrams of EPA and DHA per day, yet actual intake levels are significantly lower in many regions.

To delve deeper into the health implications of low omega-3 intake, Fox News Digital consulted with Michelle Routhenstein, a preventive cardiology dietitian based in New York at Entirely Nourished. Routhenstein confirmed that low omega-3 levels can adversely affect heart health, cognitive function, and inflammation throughout the body.

According to Routhenstein, insufficient omega-3 intake can elevate the risk of heart attacks and sudden cardiac death. It is also associated with higher triglyceride levels, irregular heart rhythms, and plaque buildup in the arteries. Furthermore, inadequate omega-3 levels have been linked to cognitive decline, a heightened risk of Alzheimer’s disease, and increased rates of depression.

Routhenstein pointed out that low omega-3 levels may exacerbate inflammation in autoimmune conditions, such as psoriasis, and can negatively impact eye health, as omega-3s play a crucial structural role in the retina.

To improve omega-3 levels, Routhenstein emphasized the importance of understanding both the required intake and the best sources of these essential fats. She noted that the richest dietary sources of EPA and DHA are oily fish, including salmon, mackerel, sardines, herring, trout, and anchovies. For many individuals, consuming oily fish three to four times per week can be beneficial.

For those who do not regularly eat fish, omega-3 supplements can help raise EPA and DHA levels to healthier ranges. Routhenstein advised that dosing for omega-3 supplements should be tailored based on lab results, medications, omega-3 levels, and overall medical history. Generally, moderate, quality-controlled supplements are considered safe for most individuals.

There is also evidence supporting the use of prescription-strength omega-3 products. Routhenstein noted that high-dose EPA, such as 4 grams per day of icosapent ethyl, has been shown to reduce major cardiovascular events in certain high-risk populations. However, similar doses of mixed EPA/DHA have not consistently demonstrated the same benefits.

Testing omega-3 levels can provide insight into whether an individual’s intake is adequate. The omega-3 index, a blood test that measures EPA and DHA in red blood cells, is regarded as one of the most reliable methods for assessing omega-3 status. Routhenstein explained that levels around 8% are associated with a lower cardiovascular risk, while levels below approximately 4% are considered low.

Understanding one’s baseline omega-3 levels can help guide more personalized dietary and supplementation decisions. Individuals who are uncertain about their omega-3 status or whether supplementation is appropriate are encouraged to consult with a healthcare provider to determine the best course of action.

According to Routhenstein, addressing omega-3 deficiency could play a significant role in improving overall health and reducing the risk of serious health issues.

At a recent FDA panel, Marius Pharmaceuticals CEO Shalin Shah and other experts advocated for a significant overhaul of testosterone therapy regulations to enhance treatment access and align with modern healthcare practices.

WASHINGTON, DC: Shalin Shah, CEO of Marius Pharmaceuticals, joined a panel of experts at the U.S. Food and Drug Administration (FDA) on Wednesday to advocate for expanded access to testosterone therapy. This session was part of a series of discussions the FDA has initiated this year to gather insights from medical professionals regarding potential regulatory changes.

During the panel, FDA Commissioner Marty Marky expressed the agency’s commitment to understanding the complexities surrounding testosterone therapy without preconceived biases. Dr. Brian Christine, Assistant Secretary for Health at the Department of Health and Human Services (HHS), emphasized the importance of the panel, noting that discussions about men’s hormonal health have long been overlooked. He described the gathering as a pivotal moment in addressing these critical health issues.

Shah, alongside other notable panelists including Dr. Landon Trost, director of the Male Fertility and Peyronie’s Clinic in Orem, Utah; Dr. Helen Bernie, associate professor of urology at the Indiana University School of Medicine; and Dr. John Mulhall, urologic surgeon at Memorial Sloan Kettering Cancer Center in New York, called for a modernization of outdated medical and regulatory frameworks. Shah argued that these frameworks currently hinder millions of men from receiving necessary care for testosterone deficiency, a condition that can significantly impact overall health.

“The FDA, with its global leadership on healthcare standards, has the opportunity to drive a framework that can impact half a billion men and women globally who need testosterone and hormone therapy,” Shah stated.

The panel focused on Testosterone Replacement Therapy (TRT), a treatment designed for men whose bodies do not produce sufficient testosterone. The panelists strongly advocated for increasing access to TRT, highlighting the health issues associated with low testosterone levels, which can lead to decreased libido, fatigue, mood changes, and loss of muscle mass.

In 2015, the FDA mandated significant label changes for testosterone products, introducing warnings about potential risks of heart attack and stroke and restricting approved use to men with confirmed hypogonadism. Shah praised the FDA for reconsidering the scientific evidence surrounding testosterone deficiency, arguing that current regulations are based on outdated fears rather than medical facts.

“Testosterone deficiency is a disease amplifier,” Shah explained. “There is an androgen receptor on nearly every organ in our body, and our body should not be devoid of this critical hormone.” He pointed out that prior to the 2015 label changes, clinicians were able to treat testosterone deficiency without needing to meet stringent criteria, similar to how other medical conditions are managed.

Shah noted that recent advancements in testosterone therapy have brought renewed hope to millions of men experiencing low testosterone levels. Marius Pharmaceuticals, founded by Indian American entrepreneur Himanshu Shah, introduced Kyzatrex, an oral testosterone drug aimed at treating adult men with low or absent testosterone levels due to specific medical conditions.

Despite the potential benefits of TRT, Shah and other panelists highlighted that it has been underutilized due to lingering concerns linking it to prostate cancer, stroke, and heart disease. Shah framed testosterone therapy not as a means of enhancement but as a vital preventive tool against chronic diseases. He urged the FDA to expedite the approval process for broader indications that recognize testosterone deficiency as a critical component of managing comorbid metabolic diseases.

Shah also drew attention to the rise of GLP-1 medications, such as Ozempic and Wegovy, which are used for weight loss but can lead to rapid muscle loss. He warned that this trend underscores the urgent need for regulatory action regarding testosterone therapy.

“A massive case study is unfolding before our eyes,” Shah remarked, noting that nearly 20% of American adults have tried or are currently using GLP-1 drugs. “Shockingly, 40% of the weight loss that occurs is lean muscle.” He contrasted the billions spent by pharmaceutical companies on new, experimental treatments with the underutilization of existing hormonal therapies, calling for a decisive action from the FDA.

Shah criticized the structural failures within the healthcare system that create barriers to preventive care, including insurance limitations and regulatory inconsistencies. He shared that Marius launched Kyzatrex as a cash-only model to ensure direct access for patients, emphasizing that the traditional medical system often does not prioritize preventive care.

He proposed that the framework for testosterone therapy should begin with improved testing and coverage. Shah highlighted the challenges men face in obtaining testosterone level tests and advocated for mandatory screening, particularly for those with metabolic dysfunctions such as depression.

“The U.S. Preventive Services Task Force should implement mandatory coverage to support this framework,” he urged. He also called for equal coverage of all testosterone formulations, including oral therapies like Kyzatrex, by Medicare and commercial insurers.

Shah suggested that the Department of Health and Human Services consider testosterone therapy an essential health benefit, which would help reduce access barriers for millions of men. He noted that Marius Pharmaceuticals is committed to supporting government efforts to make testosterone therapy affordable.

In a pointed critique, Shah addressed the legal classification of testosterone, arguing that it is regulated more strictly than substances with higher abuse potential. He provided financial data from the Department of Veterans Affairs, which indicated that normalizing testosterone levels in hypogonadal men led to significant reductions in mortality and cardiovascular events.

“In the VA, normalization of testosterone in over 80,000 hypogonadal men was associated with a 56% lower all-cause mortality and meaningful reductions in heart attacks and strokes,” Shah stated. He emphasized that applying these results on a national scale could yield substantial savings for the healthcare system.

Shah concluded by asserting that addressing low testosterone is not merely a cosmetic issue but a significant preventive care opportunity. “This doesn’t count frailty, falls, dementia, productivity, and other benefits. For Medicare and our healthcare system, low testosterone is a multibillion-dollar preventive care opportunity,” he said.

According to The American Bazaar, Shah’s remarks at the FDA panel reflect a growing recognition of the importance of testosterone therapy in modern healthcare.

The shingles vaccine may reduce dementia risk by 20% in older adults, according to a new study from Stanford Medicine, suggesting a potential cause-and-effect relationship.

A recent study from Stanford Medicine indicates that the shingles vaccine could significantly lower the risk of developing dementia among older adults. This research provides the first evidence suggesting a possible cause-and-effect relationship between shingles vaccination and dementia prevention.

According to the findings, older adults who received the shingles vaccine were found to be 20% less likely to develop dementia over a seven-year period compared to those who did not receive the vaccine. Dr. Pascal Geldsetzer, assistant professor of medicine and senior author of the study, emphasized the importance of these findings, stating, “For the first time, we now have evidence that likely shows a cause-and-effect relationship between shingles vaccination and dementia prevention and treatment.”

The study utilized public health data from Wales, where eligibility for the shingles vaccine, known as Zostavax, was determined by birth date. This unique situation created two nearly identical groups of older adults—those born just before the cutoff who qualified for the vaccine and those born just after who did not. This design allowed researchers to compare dementia rates while minimizing biases typically found in observational studies.

Following an initial analysis conducted in April, researchers delved deeper into the data and discovered that the benefits of the vaccine extended beyond just preventing dementia. Over a nine-year period, individuals who received the vaccine were less likely to be diagnosed with mild cognitive impairment. Moreover, those who were vaccinated after receiving a dementia diagnosis had a significantly lower risk of dying from dementia within the following nine years. This suggests that the vaccine may also slow the progression of the disease.

In the follow-up period, nearly half of the Welsh seniors diagnosed with dementia at the start of the vaccination program ultimately died from the condition. In contrast, only 30% of those who had received the vaccine experienced the same fate.

Dr. Geldsetzer noted, “There is a growing body of research showing that viruses that preferentially target your nervous system and hibernate in your nervous system for much of your life may be implicated in the development of dementia.” This includes the chickenpox virus, which remains dormant in the body and can reactivate in older age, leading to shingles. Such reactivation may trigger inflammation in or around the brain, a factor linked to dementia risk, according to experts from the Mayo Clinic.

Preventing viral flare-ups through vaccination could potentially reduce inflammation, thereby lowering the risk of dementia. However, the researchers acknowledged a significant limitation in their study: the health behaviors of vaccinated individuals may differ from those who are unvaccinated. Dr. Geldsetzer pointed out, “We have very little, if any, information on these behaviors in electronic health records or medical claims data.” This lack of data includes crucial factors such as dietary habits and physical activity levels.

Dr. Geldsetzer further emphasized the potential implications of their findings, stating, “If the shingles vaccine really prevents or delays dementia—and, with this new study, also appears to have benefits for those who already have dementia—then this would be a hugely important finding for clinical medicine, population health, and research into the causes of dementia.”

Fox News Digital has reached out to manufacturers of the shingles vaccine for comments regarding the study.

Source: Original article

Experts weigh in on CoQ10 supplements, highlighting their potential benefits for energy and heart health while cautioning against misconceptions and emphasizing the importance of medical guidance.

Coenzyme Q10, commonly referred to as CoQ10, has gained popularity as a supplement believed to enhance energy levels and support heart health. However, the actual benefits may not align with the high expectations many have for this compound.

CoQ10 is a natural substance found in every cell of the body, where it plays a crucial role in converting food into usable energy. Additionally, it functions as an antioxidant, protecting cells from damage caused by daily wear and tear. As people age, CoQ10 levels tend to decline, and certain medications may further reduce these levels. Consequently, many individuals turn to CoQ10 supplements, which are often marketed for various health benefits, including heart health, energy enhancement, muscle recovery, and even cognitive protection.

Before adding CoQ10 to your health regimen, it is essential to consider the insights provided by cardiologists and health experts. According to the National Center for Complementary and Integrative Health (NCCIH), while CoQ10 is important for bodily functions, the clinical evidence supporting its ability to prevent or treat diseases remains inconclusive. Some studies indicate that CoQ10 may help lower blood pressure slightly or alleviate fatigue associated with cholesterol-lowering medications. However, large-scale, well-designed trials have yet to confirm significant benefits for conditions such as Parkinson’s disease or heart disease.

Despite the uncertainty surrounding its effectiveness, experts generally agree that CoQ10 is safe for most individuals. The primary side effects reported are mild, including upset stomach and insomnia. However, the NCCIH warns that CoQ10 can interact with certain medications, particularly blood thinners and insulin, necessitating caution.

Cardiologists express interest in CoQ10 but remain cautious. A 2022 press release from the American College of Cardiology (ACC) identified CoQ10 as one of several micronutrients potentially linked to reduced cardiovascular risk and a decrease in all-cause mortality. Nonetheless, the ACC emphasized the need for more high-quality studies before recommending CoQ10 universally.

One of the reasons for caution is that CoQ10 may help relax blood vessels, which can lead to lower-than-expected blood pressure in some individuals. Unlike prescription medications, dietary supplements are not strictly regulated by the FDA, meaning the amount of CoQ10 in each capsule can vary significantly between brands. To ensure quality and purity, it is advisable to choose products that have undergone third-party testing, such as those bearing the U.S. Pharmacopeia (USP) seal.

CoQ10 is fat-soluble, which means it is best absorbed when taken with a meal containing healthy fats. The National Institutes of Health recommends a daily intake of between 100 mg and 200 mg for most individuals, although it is wise to consult with a healthcare provider to determine the appropriate dosage for your specific needs.

While experts agree that CoQ10 is generally safe and may offer some benefits, they caution against viewing it as a miracle solution. Individuals with heart failure or frequent migraines may experience positive effects from the supplement, but it is crucial to discuss its use with a healthcare professional first.

For those seeking to improve heart health, experts continue to advocate for a comprehensive approach that includes regular exercise, a balanced diet, and care supervised by a medical professional.

Source: Original article

Kim Kardashian recently revealed that a brain aneurysm was discovered during an MRI scan, prompting experts to discuss the condition’s causes, symptoms, and treatment options.

Kim Kardashian has opened up about a recent health scare involving a brain aneurysm. The 45-year-old Skims founder shared the news in a preview clip for Season 7 of Hulu’s “The Kardashians,” where she informed her family, “There was a little aneurysm.” While the exact cause of the aneurysm remains unidentified, Kardashian’s doctors have suggested that stress may be a contributing factor.

A brain aneurysm occurs when a blood vessel in the brain balloons, which can lead to leakage or rupture, resulting in bleeding. According to the Mayo Clinic, this condition can be serious and potentially life-threatening. Dr. Adam Arthur, chairman of neurosurgery at the University of Tennessee, explained that an aneurysm represents a weakness in the wall of an artery, likening it to a small water balloon forming off a hose. If an aneurysm ruptures, it can lead to a hemorrhagic stroke, which can have devastating consequences.

Dr. Arthur noted that while most aneurysms are small and do not pose a significant risk if they remain unruptured, they are more prevalent in women. He indicated that genetics may play a role in this disparity, stating, “There’s so much about the brain and about genetics that we don’t understand.” It is estimated that aneurysms are present in approximately one in every 50 individuals, and many do not require treatment.

When an aneurysm becomes problematic, it can cause a sudden stroke, often characterized by what patients describe as “the worst headache of their life.” Dr. Arthur elaborated on this symptom, describing it as a “very abnormal headache, often behind the eye.” He expressed relief that Kardashian’s aneurysm was discovered before it could lead to a stroke, calling it “a blessing.”

Several factors can increase the likelihood of aneurysm formation. These include binge drinking, exposure to nicotine, certain genetic conditions, and the use of drugs such as cocaine and methamphetamine. Dr. Arthur emphasized that drugs and nicotine can adversely affect blood vessel health, contributing to aneurysm growth and rupture. Chronic stress has also been linked to the condition, highlighting the importance of maintaining a healthy lifestyle that includes adequate sleep, a balanced diet, and regular exercise.

Understanding family history is crucial when it comes to aneurysms. Dr. Arthur recommends that individuals with two close relatives who have experienced aneurysms should consider undergoing screening exams, such as MRIs.

While some aneurysms can lead to sudden fatal strokes, those experiencing symptoms—particularly intense headaches—should seek medical attention to explore treatment options. If an aneurysm is detected before it ruptures, minimally invasive surgery may be performed to prevent a stroke. Alternatively, open surgery can be conducted, where a surgeon can pinch the aneurysm shut through an incision along the hairline.

For older patients with smaller aneurysms, monitoring by a physician is often the preferred approach to ensure that the aneurysm does not grow or cause further complications. “We do have ways of fixing aneurysms now that are pretty remarkable,” Dr. Arthur stated. He explained that medical professionals can place a metal mesh over the opening of the aneurysm or fill it with a device, allowing the body to form a clot and scar tissue over time.

Stroke remains the leading cause of disability in the United States, with Dr. Arthur noting that it “disables way more people than it outright kills.” This underscores the importance of awareness and early detection of brain aneurysms.

Fox News Digital’s Christina Dugan Ramirez contributed to this report. Fox News Digital reached out to Kardashian for comment.

Source: Original article

Dr. C. Bob Basu has been appointed President of the American Society of Plastic Surgeons, aiming to enhance member resources and uphold high standards in patient care.

Dr. C. Bob Basu has officially assumed the role of President of the American Society of Plastic Surgeons (ASPS), the largest global association of board-certified plastic surgeons. His term commenced on October 12 during the Society’s annual scientific meeting held in New Orleans.

Based in Houston, Dr. Basu leads Basu Aesthetics + Plastic Surgery and brings a wealth of surgical experience to his new leadership position, having performed over 18,000 procedures throughout his career. As president of ASPS, he intends to leverage emerging technologies, including artificial intelligence, to enhance the services and resources available to the Society’s more than 11,000 members worldwide.

In his inaugural address, Dr. Basu emphasized his commitment to maintaining the highest standards in ethics, patient safety, education, and surgical training. He highlighted the growing interest in cosmetic procedures and urged patients to seek care exclusively from board-certified plastic surgeons to ensure their safety and well-being.

Dr. Basu’s tenure in ASPS leadership spans nearly two decades. He previously served as Vice President of Finance and Treasurer, playing a crucial role in guiding the organization through challenges posed by the COVID-19 pandemic while achieving record financial performance. His contributions extend to health policy, surgical education, and governance within ASPS.

Dr. Basu holds a bachelor’s degree from Princeton University, as well as both an MD and MPH from Tufts University, and an MBA from Brandeis University. He completed his plastic surgery training at Baylor College of Medicine’s Department of Surgery before establishing his practice and reputation in Houston.

As he embarks on this new chapter, Dr. Basu’s leadership is expected to influence the future of plastic surgery, focusing on innovation and the highest standards of patient care.

Source: Original article